Payment overview · 2025
General Payments
$21,430.68
20 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel Lebovic, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · GROSSE POINTE WOODS, MI · NPI 1740302850
Verified facts
What the public records show
CMS Open Payments records show Daniel Lebovic, M.D. received $21,430.68 in general payments during 2025 across 20 reported records.
GENZYME CORPORATION accounted for 65.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Besremi, Ojjaara.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Venclexta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ojjaara by this doctor in 2024.
PharmaEssentia USA Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BESREMI as an associated drug or biological on 6276 records involving 3476 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Besremi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $13,993.18 | 65.3% | 6 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $7,245.00 | 33.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $119.63 | 0.6% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $34.48 | 0.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.89 | 0.1% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $15.50 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,889.00 | 7 |
| Food and Beverage | $335.88 | 12 |
| Travel and Lodging | $205.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $13,966.80 | 5 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $7,245.00 | 4 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $81.76 | 4 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $81.76 | 4 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BESREMI besremi |
2025 | Besremi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PharmaEssentia USA Corporation Exact reporting entity; no affiliate inference |
2025 | BESREMI open payments reported associated product |
CMS Open Payments — General Payments 6276 supporting records · 3476 recipient NPIs · example record 1246822425 |
Besremi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 215 | 49 |
| Eliquis | Apixaban | 152 | 38 |
| Hydroxyurea | Hydroxyurea | 140 | 32 |
| Revlimid | Lenalidomide | 97 | 17 |
| Dexamethasone | Dexamethasone | 88 | 26 |
| Lenalidomide | Lenalidomide | 77 | suppressed |
| Imbruvica | Ibrutinib | 64 | suppressed |
| Venclexta | Venetoclax | 54 | suppressed |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Brukinsa | Zanubrutinib | 45 | suppressed |
| Gabapentin | Gabapentin | 45 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 26 | suppressed |
| Bosulif | Bosutinib | 25 | suppressed |
| Pomalyst | Pomalidomide | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Sprycel | Dasatinib | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Besremi | Ropeginterferon Alfa-2b-Njft | 13 | suppressed |
| Deferasirox | Deferasirox | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 12 | suppressed |
| Vonjo | Pacritinib Citrate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,430.68 · 20 records | GENZYME CORPORATION | AYVAKIT, BESREMI, BLENREP, JEMPERLI, OJJAARA, Polivy, SARCLISA, Tibsovo, Trodelvy, ZEJULA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Besremi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Genentech USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error